[News Space=Reporter seungwon lee] CGBIO (CEO Yoo Hyeon-seung), a bio-regenerative medicine company and affiliate of Daewoong Pharmaceutical, announced on the 28th that it has further solidified its position in the global beauty and plastic surgery market by participating in the 'IMCAS WORLD CONGRESS 2025' (hereinafter IMCAS 2025) held in Paris, France.

IMCAS (International Master Course on Aging Science) is a global aesthetic and plastic surgery academic conference. This year, it boasts the world's largest scale, with 21,211 medical professionals from 136 countries, 1,061 speakers, and 374 exhibitors attending.

At this event, CGBIO operated a separate booth and showcased its main aesthetic product lines, including fillers ‘Facetem’, ‘AiLEENE’, ‘GISELLELIGNE’, and PDO (Polydionanone) material suture ‘LUXX’, and focused on expanding global partnerships and strengthening brand awareness.

At this event, CGBIO signed a supply contract (worth 15 billion won over 3 years) for the suture 'LUXX' with 'Cimed', a major Brazilian OTC pharmaceutical company, and confirmed orders worth a total of 4 billion won on site with Brazil, Argentina, Colombia, and Peru.

In addition, the company signed a supply contract (worth 12 billion won over 3 years) with Greece, Iraq, and Israel for fillers 'Facetem' and 'GISELLELIGNE', and won contracts worth a total of 17.3 billion won for 'Facetem', 'AiLEENE', and 'GISELLELIGNE' with 18 countries including Spain, the UK, Italy, Portugal, Greece, and Saudi Arabia, accelerating the expansion of the global market.

In addition, as part of its program, CGBIO introduced the latest calcium hydroxyapatite (CaHa)-based whole body regenerative treatment techniques to medical professionals through a lecture by Dr. Renato Pazzini, a Brazilian dermatologist. The lecture was held in the IMCAS Open Stage - Industry Sponsored Lectures session.

In addition, the latest beauty and plastic surgery trends and treatment techniques were shared through the medical staff education program 'Meet the Master' in Europe and the Middle East. Dr. Koriakina Olga, a Portuguese dermatologist, presented a non-surgical facial rejuvenation solution using CaHa-based fillers and a technique for improving wrinkles around the mouth using 'Aileene', a hyaluronic acid (HA)-based filler.

Dr. Erivan Perez Montilla, a Portuguese plastic surgeon, introduced the optimal lifting technique using the lifting filler 'Facetem' and the PDO material suture 'LUXX', and Dr. Mark McKelvie, a British dermatologist, shared various application cases of the 'GISELLELIGNE' filler and new treatment possibilities.

Hyunseung Yoo, CEO of CGBIO, said, “Through this IMCAS WORLD CONGRESS 2025, we were able to confirm once again that Sijibio’s innovative products are competitive in the global market.” He added, “We will continue to strengthen Sijibio’s position in the global market through research and development (R&D) and expansion of our global network, and lead the global beauty and plastic surgery market with our differentiated technological prowess.”

In the future, CGBIO plans to continuously pursue the discovery of new distributors in Europe, the Middle East, and the CIS (Commonwealth of Independent States) regions, while strengthening product development and marketing strategies in line with the latest trends.